Sanofi India Limited
NSE: SANOFIMarket Closed • NSE
Day range
52 week range
Sanofi India Limited closed at INR2945.40 (-1.15%) on volume 0.68x its 20-day average, trading 39.87% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -18.6% QoQ
2026-04-22
DIVIDEND Announced
Dividend - Rs 48 Per Share
2025-11-07
DIVIDEND Announced
Interim Dividend - Rs 75 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 49.2%
High Cash Flow Conversion: CFO/PAT averaged 1.34x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 1.78x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - General.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 22 Apr 2026 | Dividend | ₹48.00 / share | — | 22 Apr 2026 |
| 07 Nov 2025 | Dividend | ₹75.00 / share | — | 07 Nov 2025 |
| 25 Apr 2025 | Dividend | ₹117.00 / share | — | 25 Apr 2025 |
| 13 Jun 2024 | Demerger | Demerger | — | 13 Jun 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 03 May 2024 |
| 03 May 2024 | Dividend | ₹117.00 / share | — | 03 May 2024 |
| 07 Mar 2024 | Dividend | ₹50.00 / share | — | 07 Mar 2024 |
| — | Dividend | ₹194.00 / share | — | 28 Apr 2023 |
| 08 Aug 2022 | Dividend | ₹193.00 / share | — | 05 Aug 2022 |
| — | Dividend | ₹181.00 / share | — | 12 Apr 2022 |
| — | Dividend | ₹125.00 / share | — | 19 Apr 2021 |
| — | Dividend | ₹106.00 / share | — | 29 Jun 2020 |
| — | Dividend | ₹66.00 / share | — | 25 Apr 2019 |
| 07 Aug 2018 | Dividend | ₹18.00 / share | — | 06 Aug 2018 |
| — | Dividend | ₹53.00 / share | — | 26 Apr 2018 |
| 01 Aug 2017 | Dividend | ₹18.00 / share | — | 31 Jul 2017 |
| — | Dividend | ₹50.00 / share | — | 25 Apr 2017 |
| 05 Aug 2016 | Dividend | ₹18.00 / share | — | 04 Aug 2016 |
| — | Dividend | ₹25.00 / share | — | 13 Apr 2016 |
| 30 Jul 2015 | Dividend | ₹18.00 / share | — | 29 Jul 2015 |
| — | Dividend | ₹24.00 / share | — | 16 Apr 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
IndiaHealthcare
Is Sanofi India Limited Shariah compliant?
Sanofi India Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (178%) exceeds AAOIFI threshold (≤ 33%).
What is Sanofi India Limited's current valuation relative to peers?
Sanofi India Limited trades at a P/E of 21.0x compared to the sector median of 37.6x, and a Price-to-Book of 8.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 1.78x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -8.4% while net profit growth averaged -11.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.